Open | - |
Close | - |
Volume / Avg. | 4.993K / 537.845K |
Day Range | - - - |
52 Wk Range | 0.136 - 1.520 |
Market Cap | $20.759M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 70 |
Short Interest | 0.07% |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Pieris Pharmaceuticals (NASDAQ: PIRS) through any online brokerage.
Other companies in Pieris Pharmaceuticals’s space includes: Galecto (NASDAQ:GLTO), OncoCyte (NASDAQ:OCX), T2 Biosystems (NASDAQ:TTOO), Lumos Pharma (NASDAQ:LUMO) and NuCana (NASDAQ:NCNA).
The latest price target for Pieris Pharmaceuticals (NASDAQ: PIRS) was reported by Baird on Friday, March 13, 2020. The analyst firm set a price target for 5.00 expecting PIRS to rise to within 12 months (a possible 2280.95% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Pieris Pharmaceuticals (NASDAQ: PIRS) is $0.21 last updated Today at March 19, 2024 at 5:19 AM EDT.
There are no upcoming dividends for Pieris Pharmaceuticals.
Pieris Pharmaceuticals’s Q1 earnings are confirmed for Wednesday, May 8, 2024.
There is no upcoming split for Pieris Pharmaceuticals.
Pieris Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.